Thank you for visiting the Contemporary Pediatrics website. Take a look at some of our top stories from the past week (Monday, January 19, to Friday, January 23, 2026) and click on each link to read and watch anything you may have missed.

Hypertensive pregnancies, optimized intervention, and long-term blood pressure, with Winok Lapidaire, PhD

A randomized clinical trial published in JAMA in November 2023 demonstrated that structured self-monitoring of blood pressure with physician-guided medication titration in the early postpartum period led to significantly lower blood pressure through nine months after delivery among women with hypertensive pregnancies. Although the trial’s primary endpoints focused on blood pressure, the findings have taken on renewed relevance following downstream analyses linking postpartum blood pressure control to cardiovascular and neurologic outcomes.

Click here to watch the video interview.

Prenatal acid-suppressive medications not linked to neuropsychiatric disorders in offspring

A large population-based study published in JAMA Women’s Health found no evidence that prenatal exposure to acid-suppressive medications increases the risk of neuropsychiatric disorders in children when accounting for shared familial factors. While modest associations were observed in conventional models, no links in sibling-controlled analyses were observed, suggesting that unmeasured confounding rather than medication exposure may explain earlier concerns.

Click here for more.

How to avoid barriers for user-administered injectable contraceptives, with Jennifer Karlin, MD, PhD

Outdated FDA labeling, insurance uncertainty, and lack of clinic workflows are some barriers Jennifer Karlin, MD, PhD, and colleagues found for user-administered injectable contraceptives.

The study previously identified a substantial gap between awareness and use of self-injected DMPA, with 74.5% of clinicians reporting awareness but only 34.8% actively prescribing it. In additional interview data, Karlin said many of the remaining barriers are not clinical, but structural.

Click here for more.

RE104 30 mg demonstrates efficacy and safety in new phase 2 data for postpartum depression

• A single 30 mg dose of RE104 produced rapid and sustained reductions in depressive symptoms in women with moderate-to-severe postpartum depression.
• Clinically meaningful improvements were observed across depression, anxiety, and maternal functioning measures.
• Reunion Neuroscience plans to initiate a pivotal Phase 3 trial of RE104 in 2026.

Click here for more.

Prenatal factors and offspring risk of adult multiple sclerosis

A large population-based cohort study suggests that susceptibility to multiple sclerosis (MS) may begin as early as the prenatal period, with certain adverse pregnancy-related factors linked to MS risk in adulthood. The findings come from an analysis of more than 1.3 million individuals born in Norway and followed into adulthood, recently published in JAMA.

Click here for more.